Drug intelligence / Profile preview

polyvalent allogeneic cell vaccine

Development stage: Preclinical
Lead developer: CancerVax
Modality: Cell Therapies, Vaccines & Immunotherapeutics
Administration: Intramuscular, Intradermal, Intratumoral

Overview

PACV (polyvalent allogeneic cell vaccine) is an active immunotherapy designed to treat recurrent metastatic melanoma. This vaccine aims to re-stimulate specific immune responses in patients, which has been correlated with improved survival following recurrence and adjuvant immunotherapy. It utilizes allogeneic cells, meaning cells from a donor, to present a broad range of antigens to the immune system, thereby eliciting a robust anti-tumor response.

Beyond the preview

Go deeper on polyvalent allogeneic cell vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on polyvalent allogeneic cell vaccine.

Explore the full profile